Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Revenue
Intercept Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Revenue
$317.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
69%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Intercept Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Intercept Pharmaceuticals Inc
Breakdown by Segments
Intercept Pharmaceuticals Inc
Total Revenue:
285.7m
USD
|
Product:
285.7m
USD
|
See Also
What is Intercept Pharmaceuticals Inc's Revenue?
Revenue
317.7m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Revenue amounts to 317.7m USD.
What is Intercept Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
69%
Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Intercept Pharmaceuticals Inc have been 2% over the past three years , 14% over the past five years , and 69% over the past ten years .